Cargando…
Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
Allogeneic hematopoietic cell transplantation (allo HCT) remains a valuable alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on allo HCT outcomes in the era of new HL therapies are needed. We evaluated 72 R/R HL patients who received reduced intensity conditioning (RIC) allo HCT...
Autores principales: | Hegerova, Livia, Cao, Qing, Lazaryan, Aleksander, McClune, Brian L., Weisdorf, Daniel J., Brunstein, Claudio G., Bachanova, Veronika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415418/ https://www.ncbi.nlm.nih.gov/pubmed/28134921 http://dx.doi.org/10.1038/bmt.2016.357 |
Ejemplares similares
-
BEAM Conditioning Is Well Tolerated and Yields Similar Survival in Obese and Non-Obese Patients with Lymphoma: No Requirement for Weight-Based Dose Modifications
por: Fair, Christina, et al.
Publicado: (2017) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013) -
Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018) -
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)